03 Jun 2026

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)

05 May 2026

Announcement from the annual general meeting in Xbrane Biopharma AB

05 May 2026

Xbrane Biopharma AB’s (publ.) (”Xbrane”) Interim Report January-March 2026, is as of today, available on the Company’s website, www.xbrane.com.

05 May 2026

Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities

05 May 2026

Valuation expert Venture Valuation provides external valuation of Xdivane program

30 Apr 2026

XBRANE SUBMITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

31 Mar 2026

Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States

31 Mar 2026

NOTICE OF ANNUAL GENERAL MEETING IN XBRANE BIOPHARMA AB

31 Mar 2026

Xbrane has released the company’s 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.

20 Feb 2026

Xbrane Biopharma releases Year-end Report 2025

13 Feb 2026

Invitation to presentation of Xbrane Biopharma’s Year-end report 2025 on February 20, 2026

24 Nov 2025

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

19 Nov 2025

XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

04 Nov 2025

First patient included in Xdivane pivotal clinical trial

03 Nov 2025

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.